Introduction {#s1}
============

Huntington\'s disease (HD) is a fatal neurodegenerative disorder characterized by cognitive and psychiatric disturbances that are associated with loss of motor control, including chorea, dystonia, and a lack of gestural coordination (Novak and Tabrizi, [@B111]). These symptoms generally start to appear in midlife. A broad range of cognitive disturbances appear during HD progression. Early cognitive defects are characterized by poor adaptation and planification associated with deficits in executive functioning and perseveration. Other defects are most prevalent during the late stages of the disease, like learning difficulties and working and long term memory deficits, leading to dementia (Rosenblatt, [@B136]; Paulsen, [@B116]).

HD is caused by an abnormal expansion of glutamine (polyQ) in the N-terminal part of the 350 kDa protein huntingtin (HTT). This stretch is encoded by a trinucleotide CAG repetition in exon 1 of *HTT*. An expansion greater than 36 repeats results in HD (Huntington Collaborative Research Group, [@B133]). The number of repeats is inversely correlated with the age of onset of motor symptoms and disease onset during childhood or adolescence is associated with more than 60 CAG repeats (Walker, [@B165]). HD is inherited in an autosomal dominant manner. Genetic and molecular studies have suggested that mutated polyQ-HTT leads to neuronal damage by gain of toxic function. The pathogenic mechanism requires the cleavage of full-length HTT into smaller N-terminal fragments that contain the polyQ stretch that have been shown to be highly toxic in HD cellular and mouse models (Gafni et al., [@B46]; Graham et al., [@B54]). However, there is strong evidence that loss of the normal functions of wild-type HTT also plays a role in pathological mechanisms of HD.

Mood disorders in patients with HD
==================================

Mood disturbances are prevalent not only among patients with diagnosed HD but also in pre-symptomatic carriers of the HD gene (Duff et al., [@B36]; Julien et al., [@B68]; Rosenblatt, [@B136]) (Table [1](#T1){ref-type="table"}). These disturbances include impulsivity, irritability (which can be accompanied by aggressiveness), anxiety, and depression. Major depression is the most common symptom among pre-symptomatic HD carriers, although some patients will have only part of the symptoms of the major depression, or limited in intensity or time (Epping and Paulsen, [@B41]; Reedeker et al., [@B130]). Maniac depressive disorder is not particularly prevalent in HD (Van Duijn et al., [@B159]; Epping and Paulsen, [@B41]). Mood disturbances may precede the onset of the motor phenotype by 4--10 years, making them one of the earliest symptoms of HD. The severity of depression in HD is not dependent on disease progression (Berrios et al., [@B10]; Craufurd et al., [@B25]; Kingma et al., [@B70]). This suggests that different mechanisms affect neurons involved in mood regulation and neurons involved in motor and cognitive skills that are disabled in late phases of the disease in HD patients. However, mood, and cognitive alterations may also share some pathogenic mechanisms as some aspects of these alterations are found associated in the general population and in HD patients. In particular, depression and memory impairments are observed together and this is also the case for cognitive flexibility and planification defects (Smith et al., [@B150]; Trivedi and Greer, [@B156]). Although apathy is part of symptoms of major depression, frequency, and intensity of apathy in HD patients increase with disease progression contrary to depression (Kingma et al., [@B70]; Van Duijn et al., [@B160]). Thus, as previously suggested (Levy et al., [@B84]), apathy appears not only as a symptom of depression but as a syndrome with its own dynamics and mechanisms.

###### 

**Clinical observations on Huntington\'s disease patients**.

  **Clinical studies (number of patients)**                                                   **Psychiatric observations**                                                                                                                                                                                            **Scale used to assess depression and/or anxiety**   **Use of pharmacologic treatments**                                                    **References**
  ------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------- -------------------------------------------------------------------------------------- ---------------------------
  217 patients with motor symptoms (comparison black vs. white patients)                      32.8% had affective disorders Age at onset of motor symptoms for persons with affective disorder was significantly later than that for persons without affective disorder (43.4 and 38.7 years, respectively).          DSM-III criteria Diagnostic Interview Schedule       ND                                                                                     Folstein et al., [@B43]
  134 patients Male subjects = 47%                                                            39% were depressed 16% had attempted suicide 34% had suicidal ideation                                                                                                                                                  UHDRS PBA-HD                                         34% were given antidepressant drugs. 24% were given sedative or anxiolytic treatment   Craufurd et al., [@B25]
  2835 patients Male subjects = 47.5%                                                         More than 40% of patients have depressive symptoms. More than 10% have attempted suicide                                                                                                                                UHDRS                                                More than 50% had received antidepressant treatments in the past                       Paulsen et al., [@B117]
  681 patients Male subjects = 46%                                                            More psychiatric symptoms (e.g., depression, anxiety, obsessive-compulsiveness) than healthy people. Higher levels of psychiatric symptoms in individuals with severe motor impairment                                  UHDRS SCL-90-R                                       ND                                                                                     Duff et al., [@B36]
  204 participants, blind to their genetic status, asymptomatic (definite HD were excluded)   20% had experienced major depression 17% had an anxiety disorder, and 11% had general anxiety. The rate of depression increased as a function of proximity to clinical onset                                            CIDI DSM-III criteria                                ND                                                                                     Julien et al., [@B68]
  254 at risk of HD or recently diagnosed participants Male subjects = 29%                    Increased anxiety score in presymptomatic carriers and patients with HD individuals. ≈25% of presymptomatic carriers and patients with HD were depressed Prevalence of symptoms increases with the progression of HD.   SCL-90-R CES-D                                       21% were given antidepressant, anxiolytic or antipsychotic treatments                  Marshall et al., [@B95]
  152 patients, including pre-symptomatic Male subjects = 45.5%                               Higher prevalence of depression in HD patients, including pre-symptomatic. No higher prevalence with development of HD                                                                                                  PBA-HD                                               ND                                                                                     Kingma et al., [@B70]
  154 patients including pre-symptomatic carriers Male subjects = 45.7%                       Higher prevalence of depression/anxiety in presymptomatic and symptomatic HD patients than average population.                                                                                                          DSM-IV criteria CIDI                                 26.4% were given antidepressant treatment                                              Van Duijn et al., [@B159]
  111 patients                                                                                Higher prevalence of neuropsychiatric symptoms in patients with HD than average population. Prevalence did not increase with the progression of HD.                                                                     PBA-HD                                               ND                                                                                     Thompson et al., [@B154]
  803 prodromal patients with HD mutation Male subjects = 36%                                 Depression prevalence higher in females.                                                                                                                                                                                BDI-II SCL-90-R UHDRS                                ND                                                                                     Epping et al., [@B40]

*BDI-II, Beck Depression Inventory; CES-D, Center for Epidemiological Studies Depression Scale; CIDI, Composite International Diagnostic Interview; DSM-III/IV, Diagnostic and Statistical Manual of Mental Disorders 3rd/4th edition; PBA-HD, Problem Behaviors Assessment for Huntington Disease; SCL-90-R, Symptom Checklist 90 Revised; UHDRS, Unified Huntington Disease Rating Scale; ND, no data*.

The reasons underlying the frequent co-morbidity of HD and mood disorder are still unclear. Family history of HD, especially given that HD shows a dominant mode of inheritance, is probably an important factor. Indeed, an individual\'s knowledge that he or she is a carrier and will inevitably experience neurological symptoms, could contribute to the prevalence of psychiatric disturbances. However, this explanation alone is not sufficient to explain the high prevalence of psychiatric disturbances in HD (Almqvist et al., [@B1]; Julien et al., [@B68]; Van Duijn et al., [@B159]). Therefore, there are probably one or several molecular mechanisms, independent of the psychosocial environment, that can explain the prevalence of mood disorders in patients or carriers of HD. This hypothesis can be tested in animal models of HD.

There is no treatment that can halt or even slow down the progression of Huntington\'s disease. Current effective treatments aim to ease the symptoms of this disease. The evidence base for drugs in HD is very small so the choice of pharmacological agents is based mainly on clinical experience. Various molecules are used to treat motor dysfunction. These include neuroleptics for chorea, and tetrabenazine (which is a dopamine-depleting agent that inhibits the vesicular dopamine transporter VMAT2) for dyskinesia. Tetrabenazine is the most effective drug for the management of HD and hence is the first choice of treatment; however, this drug induces depression and sedation in patients (Frank, [@B44]; Mestre and Ferreira, [@B100]) and similar findings were reported in a mouse model of HD (YAC128) (Wang et al., [@B167]). Stress, anxiety, and depression can aggravate chorea, so measures to treat these mood problems may also help to slow the progression of HD. Mood disorders in HD are treated by antidepressant and/or anxiolytic drugs (Table [1](#T1){ref-type="table"}). Pre-symptomatic HD carriers are almost twice as likely to be treated with antidepressants than individuals who are not carriers of HD (Rowe et al., [@B137]). At present, there is no established molecular evidence base for the treatment of depression in HD. However, antidepressants are often very effective in clinical practice (Novak and Tabrizi, [@B111]). Depression is most commonly treated with classic serotonin-specific reuptake inhibitors (SSRIs) such as citalopram or sertraline. Fluoxetine is often avoided as it exacerbates chorea and enhances anxiety, both of which frequently occur in patients with HD (Chari et al., [@B20]; Novak and Tabrizi, [@B111]). Anxiety is treated with non-stimulating SSRIs such as buspirone or benzodiazepines (Novak and Tabrizi, [@B111]).

Mouse models of HD
==================

Various rodent models have been used to study the effect of polyQ expansion in HTT (Heng et al., [@B59]; Pouladi et al., [@B124]). These models differ in the number of CAG repeats, the size of the expressed HTT fragment, and the gene promoter used. Thus, the amount of mutant HTT that is expressed varies between different models. The genetic background of the mouse strains used to design models of HD is also important, especially because various strains perform differently in behavioral tests (Miller et al., [@B101]; Mozhui et al., [@B105]). These models can be grouped according to their mode of expression of mutant HTT: transgenic models expressing truncated HTT, transgenic models expressing full-length HTT, and knock-in (KI) models.

The short lifespan of mouse models prevents them from developing the same neuropathological symptoms that develop during decades in human. Large numbers of glutamines in the polyQ stretch in the homozygous state in KI models and/or a high abundance of transgenic mutant proteins are necessary to obtain a robust phenotype. The length of the N-terminal fragments and their toxicity are inversely correlated, which underlies the robust phenotype of models in which a short N-terminal polyQ-HTT fragment is expressed (Hackam et al., [@B58]; Landles et al., [@B78]).

The sequence coding the 350 kDa HTT protein contains 67 exons spanning over 170 kb of the mouse genome. Hence, the creation of transgenic models in which full-length HTT is expressed is a difficult task. Therefore in some models, the exogenous protein is limited to the N-terminal part containing the polyQ expansion, with the assumption that this portion is sufficient to recapitulate some aspects of the disease. R6/1 and R6/2 mice carry a transgene encompassing exon 1 of *Htt* (Mangiarini et al., [@B94]). In R6/1 mice this exon contains a polyQ tract of approximately 115 residues whereas in R6/2 mice this number is 150. The progression of HD in R6/2 and R6/1 mice is particularly fast and aggressive, therefore these mice may only be suitable as models for juvenile HD, which manifests in patients with very extensive polyQ stretches. These models could also correspond to the late HD stages when HTT is cleaved and N-terminal fragments accumulate. N171-82Q mice carry a transgene encompassing the first 171 amino acids of HTT with a polyQ tract of 82 residues (Schilling et al., [@B144]).

Transgenic models expressing full-length mutant HTT contain the human *HTT* gene with an expanded CAG repeat which is randomly inserted into the mouse genome through a Yeast Artificial Chromosome (YAC) or a Bacterial Artificial Chromosome (BAC). The YAC72 model contains full length *HTT* including 72 CAG repeats and the YAC128 model contains full length *HTT* including 128 CAG repeats (Hodgson et al., [@B63]). Transgenic *HTT* in BACHD mice contains 97 CAG repeats coding for glutamine (Gray et al., [@B55]). In these models, transgenic *HTT* is under the control of the human *HTT* promoter. The endogenous wild-type form of HTT is still expressed in these models, which is also the case for models expressing a truncated form of HTT. Interestingly, mouse models expressing full-length mutant HTT generally develop motor deficits later than transgenic models with truncated HTT, which allows more time to study anxio-depressive behaviors without interference from motor impairment in these mice.

KI models are constructed by replacing the murine exon 1 of the endogenous *Htt* gene by a chimeric human/mouse sequence that includes various lengths of the CAG stretch (Menalled et al., [@B98]). Heterozygous KI HD mice thus mimic the genetic situation of human patients. KI models are also considered a more accurate genetic HD model than many transgenic models, because they express the mutated gene under the control of the endogenous mouse promoter. Thus, the mutated HTT is expressed at levels similar to the endogenous gene, and is not overexpressed as in transgenic models. This may explain why KI mice have a milder phenotype than that of transgenic mouse models. Indeed, KI strains present very little or subtle observable motor dysfunction, and a normal lifespan (Menalled et al., [@B98]). KI mouse models can be particularly useful to study the early symptoms of the disease, including anxio-depressive disorders, prior to the onset of motor impairments.

Few models have been developed to study the role of wild-type HTT. The knock-out of *Htt* is lethal early in development at embryonic day 7.5 (Duyao et al., [@B39]; Nasir et al., [@B107]; Zeitlin et al., [@B177]); therefore, Cre-Lox systems have been used to study the role of HTT in the developing nervous system or in the adult nervous system (Dragatsis et al., [@B31]; Dietrich et al., [@B29]; Pla et al., [@B122]). *CaMKCreER^*T*2^*; *Htt^flox/flox^* mice were generated to study the function of HTT in mature cortical and hippocampal neurons of adult mice. Following tamoxifen injection (in 2 month old mice), *Htt^flox/flox^* is excised specifically from the genome of these neuronal cells, hence allowing the study of HTT function in adult mice without developmental bias (Pla et al., [@B122]). KI mice containing point mutations in *Htt* have also been produced to study the role of post-translational modifications of HTT. These models involve modifications of serines 1181 and 1201 that are phosphorylated by Cdk5: mutations either mimic constitutive phosphorylation or prevent phosphorylation at these two sites (Ben M\'Barek et al., [@B8]).

Mouse models of HD present anxiety/depressive-like phenotypes
=============================================================

The anxio-depressive status of various mouse models of HD has been investigated by classical behavioral tests. Results are summarized in Table [2](#T2){ref-type="table"}.

###### 

**Anxiety and depression-related behavior in HD murine models**.

![](fnbeh-08-00135-i0001)

*Numbers indicate the age in weeks at which the phenotype was observed. Ø, no significant change; ↑, significant increase; ↓, significant decrease*.

Anxiety paradigms
-----------------

The open-field test is frequently used to assess motor activity but can also be applied to measure anxiety. During this test, mice are allowed to explore a walled enclosure for about 30 min. Mice usually spend most of their time along the walls rather than in the middle of the field, because they fear that exposure may make them vulnerable to predators. Therefore, anxiety is inversely correlated with the amount of time the mouse spends in the center, and/or the number of trips it makes from the walls to the center. It is however necessary to verify that the behavioral differences between wild-type and HD mice in this test are not due to an impaired motility of the HD animals. This is particularly important because HD models (and especially the transgenic ones) develop impairment to motor behavior. With this in mind, the most pertinent variable to measure is the "ambulatory distance/total ambulatory distance" ratio. According to this variable, male *Hdh ^Q111/Q111^* mice and *CaMKCreER^*T*2^*; *Htt^flox/flox^* mice show an anxiety-like behavior (Orvoen et al., [@B112]; Pla et al., [@B122]). R6/2 mice and YAC128 mice also spend little time in the center of the area (Ciamei and Morton, [@B23]; Chiu et al., [@B22]). However, this finding may not be significant for YAC128 mice because they also travel short distances.

The elevated plus maze (EPM) test is based on the aversion of mice to open spaces and height, and is widely-used in the study of anxiety behaviors. In R6/1 mice, anxiety-like behavior appears progressively and reaches its peak in 24 week-old mice. However, this test is difficult to interpret at this age because locomotor activity is also altered. This impairment is shown by the small number of entries that the mouse makes into both the open and closed arms of the maze (Naver et al., [@B108]; Nithianantharajah et al., [@B110]). An anxiety phenotype is observed in YAC128 mice, which spend less time in the open quadrants of the zero-maze than in the closed quadrants (Chiu et al., [@B22]). An anxiety-like behavior is also observed in *CaMKCreER^*T*2^*; *Htt^flox/flox^* mice (Pla et al., [@B122]), showing that a loss of function of HTT only in mature cortical and hippocampal neurons in adults is sufficient to lead to anxiety.

The light/dark box test is used to assess anxiety-like behaviors and is based on the aversion of mice to light. Variables that are measured include the latency to enter the lit compartment, and the time spent in each compartment. Both male and female R6/2 mice exhibit an anxiety-like behavior from 12 to 14 weeks as assessed by this test. Anxiety may start earlier in males than in females, although this is not a consistent finding (Hickey et al., [@B61]; Menalled et al., [@B98]). Menalled and colleagues also showed that 12 week-old BACHD mice spend a long time in the dark box, indicative of an anxiety-like phenotype (Menalled et al., [@B98]). CAG140 mice show a high latency to enter the lit compartment at 1.5 months of age but not at 8 months of age (Hickey et al., [@B62]). This suggests that an early anxiety-like phenotype in both males and females disappears as the disease progresses. *Hdh^Q111/Q111^* or YAC128 mice display no phenotype in this test (Chiu et al., [@B22]; Orvoen et al., [@B112]).

Anxiety-depressive paradigms
----------------------------

The novelty suppressed feeding (NSF) test is a conflict test with competing motivations: the drive to eat and the fear of venturing into the center of a brightly lit area. This test measures both anxiety and depression and the outcome of this test is sensitive to anxiolytics and chronic antidepressants, but not to acute antidepressants (David et al., [@B27]). The NSF test is also described as a "neurogenesis-dependent" test, because the ablation of neurogenesis in the hippocampus blocks the efficacy of antidepressants in this test (David et al., [@B27]). R6/1, *Hdh^Q111/Q111^*, and *CaMKCreER^*T*2^*; *Htt^flox/flox^* mice show a high latency to eat in the NSF paradigm, suggestive of anxiodepressive-like behavior in these mice (Renoir et al., [@B132]; Orvoen et al., [@B112]; Pla et al., [@B122]).

Depressive paradigms
--------------------

The sucrose preference test is used to measure anhedonia, which is a component of depressive behavior in both humans and mice. Studies show that HD mice have a lower preference for sucrose compared to wild-type mice, which represents a depressive-like behavior (Pouladi et al., [@B123]; Renoir et al., [@B132]). This behavior is sex-independent in YAC128 mice; however, the saccharin-preference of R6/1 female mice is lower than that of R6/1 male mice, or that of wild-type males or females.

In the splash test, low grooming frequency after a sucrose solution is squirted onto the mouse\'s fur can be interpreted as a loss of motivational behavior. This is thought to model some symptoms of depression, such as apathic behavior. Female, but not male *Hdh^Q111/Q111^* mice, show a depressive behavior in this test (Orvoen et al., [@B112]).

The forced swim test (FST) is widely used in pharmacology to screen for molecules with anti-depressant effects. It is also used to highlight a depressive-like behavior in rodents, linked to resignation, although the validity of this test as a measure of depression is debatable. Apart from CAG140, all of the HD models that were subjected to this test show a long duration of immobility, which indicates a depressive-like behavior in this paradigm (Grote et al., [@B57]; Hickey et al., [@B62]; Peng et al., [@B119]; Pouladi et al., [@B123]; Chiu et al., [@B22]; Renoir et al., [@B132]; Orvoen et al., [@B112]; Pouladi et al., [@B125]; Renoir et al., [@B131]). A long duration of immobility is associated with either a short swimming duration (YAC 128) (Pouladi et al., [@B123]), or a short climbing duration (*Hdh^Q111/Q111^*) (Orvoen et al., [@B112]). According to Detke et al. ([@B28]) and Page et al. ([@B113]), short swimming duration indicates an alteration in serotonergic circuitry and short climbing duration indicates an alteration in noradrenergic circuitry. In the YAC128 mouse model the severity of depressive-like phenotypes tested with FST does not increase with age or with the progression of motor symptoms (Pouladi et al., [@B123]). Furthermore, the severity of the depressive-like phenotype is not correlated with the number of CAG repeats (Pouladi et al., [@B123]), similar to the situation in HD patients (Epping et al., [@B40]). There appears to be a sex-specific component of this depressive-like phenotype. Indeed, some studies report that mutated *HTT* is associated with a depressive-like phenotype in females but not in males, and in the R6/1 model, this phenotype manifests earlier in females than in males (Grote et al., [@B57]; Pang et al., [@B115]; Renoir et al., [@B132]; Orvoen et al., [@B112]). Thus, in the FST, the depressive-like phenotype has a sex-specific component, similar to findings for the sucrose-preference test.

The tail suspension test (TST) is another widely-used test in the screening for antidepressant drugs, and is also used to measure depressive-like behavior, linked to resignation, which is a function of the amount of time that the animal stays immobile. YAC128 mice show a high degree of immobility in the TST, which is consistent with findings of the FST (Chiu et al., [@B22]). However, the findings of the FST and TST involving R6/1 mice are inconsistent: in the TST, the duration of immobility is short for female R6/1 mice aged 12 weeks, suggesting that mutated HTT actually has an "antidepressant" effect (Pang et al., [@B115]). Nonetheless, another study found that the HD mutation does not affect TST performance of R6/1 mice at 8 weeks of age compared to wild-type mice (Renoir et al., [@B132]). The immobility duration of male or female CAG140 mice does not differ from that of wild-type mice in the TST, which is consistent with FST results in this strain (Hickey et al., [@B62]).

Altogether, results from different mouse strains using various behavioral tests show that HD mice exhibit anxiety- and depressive-like behavior. In various mouse models, a sex-specific component to these behaviors is evident: HD mutant females are more prone to depressive-like behaviors than mutant males (Pang et al., [@B115]; Orvoen et al., [@B112]), whereas mutant males are more prone to anxiety-like behaviors than mutant females (Hickey et al., [@B61]; Menalled et al., [@B98]; Orvoen et al., [@B112]). In humans, depression is roughly twice as prevalent in women as it is in men, and the reason of this difference is currently unknown (Kornstein et al., [@B74]).

HTT, BDNF and mood disorders
============================

The general functions of HTT have been recently reviewed (Zuccato et al., [@B181]). Among other functions, wild-type HTT regulates the production, transport and release of BDNF, a function that is impaired when HTT is mutated or absent (see below). Microarray studies have shown that *Bdnf*^+/−^ and forebrain-specific *Bdnf*^−/−^ mice have transcription profiles similar to those of patients with HD or R6/2 mice (Strand et al., [@B152]), suggesting a major role for BDNF in the pathogenesis of HD. BDNF has been implicated in the physiopathology of mood disorders (Autry and Monteggia, [@B7]), and is thus the most obvious candidate linking HTT to mood disorders.

Wild-type HTT positively regulates *Bdnf* transcription (Cattaneo et al., [@B18]). Zuccato and colleagues showed that a neuron restrictive silencer element (NRSE) in the *Bdnf* promoter is indirectly targeted by wild-type HTT (Zuccato et al., [@B180]). Wild-type HTT inhibits the silencing activity of NRSE by sequestering its transcription factor (REST/NRSF) in the cytoplasm, leading to a high rate of *Bdnf* transcription. In contrast, in the context of HD, aberrant accumulation of REST/NRSF is observed in the nucleus, which impairs *Bdnf* transcription. Hence, one of the functions of HTT is to guarantee the sufficient production of BDNF via the sequestration of REST/NRSF. Mutated HTT also interferes with CREB function, which is an activator of *Bdnf* transcription (Zuccato et al., [@B181]). In agreement with these observations, low *BDNF* expression has been observed in various brain regions of HD patients, including frontal cortex, striatum, hippocampus, substantia nigra, and cerebellum (Zuccato et al., [@B184]; Seo et al., [@B145]). In most mouse models of HD, the abundance of BDNF protein (Duan et al., [@B34], [@B35]; Saydoff et al., [@B143]; Simmons et al., [@B147]; Xie et al., [@B170]) and *Bdnf* mRNA is decreased in mutant compared to normal mice in cortex, striatum and hippocampus (Zuccato et al., [@B178]; Pang et al., [@B114]; Zajac et al., [@B175]). It should be noted that striatal neurons express very low amount of BDNF mRNA (Altar et al., [@B3]). Therefore, the decrease of BDNF mRNA observed in striatum may not be biologically significant (as suggested in Pang et al., [@B114]). The diminished detection of BDNF at protein level in striatum may be attributed to a transport and secretion defect of neuronal BDNF coming from cortex or substantia nigra (see below). Studies have reported increased BDNF protein levels in anterior cortex or substantia nigra in R6/1 mice: this may be caused by an accumulation of BDNF linked to a transport deficit along corticostriatal or nigrostriatal pathways (Pineda et al., [@B121]; Pang et al., [@B114]) (see below).

In addition to controlling the production of *Bdnf* mRNA, wild-type HTT regulates BDNF transport. Gauthier and colleagues found that BDNF transport in microtubules is stimulated by wild-type HTT (Gauthier et al., [@B47]). In contrast, cortical BDNF transport is impaired both in the presence of low amounts of wild-type HTT and by the expression of mutant HTT (Gauthier et al., [@B47]). Similar findings have also been demonstrated in hippocampal neurons (Pla et al., [@B122]). Defects in BDNF vesicular trafficking decrease the activity-dependent release of BDNF from cortical and hippocampal neurons (Gauthier et al., [@B47]; Pla et al., [@B122]). This leads to the downregulation of the phosphorylation of AKT and Erk, both of which are regulated downstream of the interaction of BDNF with its receptor, TrkB (Pla et al., [@B122]).

HTT-mediated transport is microtubule-dependent and involves huntingtin-associated protein-1 (HAP1), which is implicated in axonal transport via its interaction with the microtubule-dependent molecular motors kinesin and dynein, as well as the dynactin subunit p150*^Glued^* (Li et al., [@B85]; McGuire et al., [@B97]; Rong et al., [@B135]). This complex is altered in the absence of HTT, or in the presence of mutated HTT containing an abnormally expanded polyQ tract. This alteration leads to the detachment of BDNF vesicles from microtubules (Gauthier et al., [@B47]; Zala et al., [@B176]).

Another argument in favor of the importance of HTT in axonal transport involves HTT phosphorylation. Indeed, HTT function is regulated by phosphorylation and the phosphorylation status of HTT affects BDNF transport and release. Phosphorylation of HTT at serine 421 by AKT and SGK specifically enhances the anterograde transport and release of BDNF at axon terminals (Humbert et al., [@B183]; Rangone et al., [@B128]; Colin et al., [@B24]). HTT is also phosphorylated at serines 1181 and 1201, which are both targets of Cdk5. In contrast to serine 421, dephosphorylation of these sites stimulates transport and release of BDNF (Ben M\'Barek et al., [@B8]).

The density or the function of TrkB, the receptor for BDNF, may also be altered due to defects in transcription and trafficking. Indeed, the transcriptional activity of *TrkB* is low in HD striatal neurons, independent of the production of BDNF (Ginés et al., [@B50]). Consistent with this finding, low amounts of TrkB are found in the caudate nucleus and/or cortex of HD post-mortem brains (Ginés et al., [@B49]; Zuccato et al., [@B179]). In addition to the transport of BDNF-containing vesicles, HTT also transports TrkB-containing vesicles. The retrograde transport of activated TrkB-containing endosomes is low in the presence of mutated HTT, leading to an impairment in neurotrophin signaling in striatal dendrites. This subsequently affects phospho-Erk and c-fos within striatal neurons (Liot et al., [@B88]). An impairment in Ras/MAPK/ERK1/2 signaling resulting from a low abundance of TrkB may also be associated with the low abundance of p52/p46 Shc docking proteins in striatal cells expressing polyQ-HTT (Ginés et al., [@B50]). Rab11 is also important for TrkB distribution in dendrites (Lazo et al., [@B81]) and defects of Rab11 recycling endosomes have been observed in HD (Li et al., [@B86]).

Therefore, by dysregulating transcription, trafficking and signaling at multiple levels, mutant HTT impairs both the ligand and the receptor in the BDNF/TrkB pathway (Figure [1](#F1){ref-type="fig"}).

![**HTT affects BDNF/TrkB signaling at many levels**. HTT regulates BDNF transcription (via the sequestration of REST/NRSF), BDNF vesicular trafficking (via interaction with the molecular motors dynein and kinesin), the activity-dependent release of BDNF, and also TrkB retrograde vesicular trafficking (via HAP1 interaction). HTT also affects Rab11-dependent endosomal recycling. HTT could also modulate TrkB endocytosis via its interaction with HAP40 and early endosomal trafficking via its interaction with Rab5. See references in the text.](fnbeh-08-00135-g0001){#F1}

However, the hypothesis that the impairment of the BDNF/TrkB pathway alone can lead to mood disorder is still a matter of debate. Most studies support the conclusion that an impairment in the production of BDNF is not associated with profound changes to depression-related behavior (Autry and Monteggia, [@B7]). Yet, in the forced swim test and in the sucrose preference test, female mice lacking BDNF show a high degree of depressive-like behavior (Monteggia et al., [@B104]). This is similar to the situation in HD, in which females are more prone to depressive-like behaviors than males. In R6/1 mice, the production of BDNF is mostly affected in females, because the abundance of a large number of *Bdnf* isoforms (BDNF I, II, III, IV and VI) is low in females, whereas in males only BDNF I and VI transcripts are affected (Zajac et al., [@B175]).

In contrast, there is a clear link between anxiety-related behavior and BDNF signaling. KI mice that express BDNF containing a point mutation (valine 66 to methionine substitution, Val/Met 66) that mimics a mutation found in human populations, show impairment in BDNF secretion and exhibit high levels of anxiety-like behavior in open field and elevated plus maze tests (Chen et al., [@B21]). Genetic or pharmacological inhibition of TrkB also results in the modification of anxiety-related behavior (Bergami et al., [@B9]; Cazorla et al., [@B19]). Conversely, antidepressants such as SSRIs, tricyclic molecules, or monoamine oxidase-A inhibitors are able to rapidly activate BDNF/TrkB signaling (Saarelainen et al., [@B140]; Rantamäki et al., [@B129]).

New discoveries have highlighted a role for BDNF production and HTT in cell types other than neurons. BDNF produced by astrocytes can modify mood-related behavior in mice (Quesseveur et al., [@B126]). Expression of a mutated fragment of HTT in astrocytes causes age-dependent neurological symptoms, including motor function deficits (Bradford et al., [@B13]). Anxiety or depressive-related behaviors were not examined in these mice and such a study would be of interest.

Finally, many studies demonstrate that the efficacy of antidepressant treatments depends on fully functioning BDNF production and signaling (Monteggia et al., [@B103]; Malberg and Blendy, [@B93]; Monteggia et al., [@B104]; Hu and Russek, [@B65]; Li et al., [@B87]). Thus, restoration of the "normal" levels of BDNF could be a therapy for HD patients. Normal levels of BDNF can be restored by physical exercise in HD models. According to Zajac et al. ([@B175]), the abundance of total *Bdnf* mRNA that is low in the hippocampus of both male and female R6/1 mice is significantly increased by wheel-running activity in female R6/1 mice and wild-type mice (but not in male R6/1 mice). Environmental enrichment is another method that promotes BDNF production. Environmental enrichment is associated with a high abundance of *Bdnf* mRNA in the hippocampus of male wild-type animals (Zajac et al., [@B175]) and environmental stimulation benefits patients with HD (Sullivan et al., [@B153]).

HTT and hippocampal adult neurogenesis
======================================

The amount of neurogenesis in the hippocampal dentate gyrus (DG) is associated with anxiety state. Intriguingly, both high or low levels of DG neurogenesis have been associated with anxiogenic behavior, suggesting that an optimal level of DG neurogenesis is important to maintain a normal anxiety-related state (Fuss et al., [@B45]). Low levels of neurogenesis alone are not sufficient to trigger a depression-like phenotype; however, neurogenesis is necessary for some of the beneficial effects of anti-depressant treatments (Samuels and Hen, [@B142]; Mendez-David et al., [@B99]).

Neurogenesis in the subventricular zone (SVZ) is increased in post-mortem HD brain tissue (Curtis et al., [@B26]). However, neurogenesis in the DG has not been examined in HD patients. In HD rodent models, adult neurogenesis is altered in the hippocampus whereas no significant alteration of neurogenesis in the SVZ has been observed (Gil et al., [@B48]; Phillips et al., [@B120]; Lazic et al., [@B80];). This suggests that the mechanism with which HTT controls neurogenesis is region-specific. The discrepancy between patients and mice regarding neurogenesis in the SVZ could be explained by the fact that the loss of striatal neurons is more detrimental for humans than for mice; thus, a compensatory activation of neurogenesis in the SVZ could be triggered in humans but not in mice (Curtis et al., [@B26]).

HD mouse models show defects in cellular proliferation in the DG, however these defects occur during the late stages of disease progression. In the DG of R6/1 mice, cell proliferation is low only when mice already exhibit motor deficits (Lazic et al., [@B79], [@B80]; Walker et al., [@B166]). Similarly, YAC 128 mice show normal cell proliferation in the DG prior to the onset of motor deficits. However, these mice have 26% fewer proliferating cells in the DG when they are 18 months old compared to wild-type mice (Simpson et al., [@B148]). No defect in cellular proliferation is observed for *Hdh^Q111/Q111^* mice before the onset of motor deficits, and similarly, cellular proliferation in the loss of function *CaMKCreER^*T*2^*; *Htt^flox/flox^* mice is not affected (Orvoen et al., [@B112]; Pla et al., [@B122]).

In contrast to proliferation, the differentiation and survival of new-born DG neurons are affected during the early stages of disease progression, before the onset of motor deficits. YAC128 mice show morphological alterations to DG immature neurons (Simpson et al., [@B148]). Male but not female *Hdh^Q111/Q111^* mice have defects of dendritic arborization of new-born DG neurons (Orvoen et al., [@B112]). This correlates well with anxiety-related behavior because only male *Hdh^Q111/Q111^* mice show anxiety-like behavior (Orvoen et al., [@B112]). This correlation extends to the loss-of-function *CaMKCreER^*T*2^; Htt^flox/flox^*model, in which anxiety-like behavior is also associated with defects of dendritic arborization and the poor long-term survival of new-born DG neurons (Pla et al., [@B122]). Conversely, in KI mice that express HTT containing non-phosphorylatable serines 1181 and 1201, an anxiolytic-like behavior is associated with an increase of dendritic arborization and survival of newborn DG neurons (Ben M\'Barek et al., [@B8]).

The deletion of *Htt* in mature cortical and hippocampal neurons affects only anxiety-related behavior and not depressive-related behavior (Pla et al., [@B122]). Female *Hdh^Q111/Q111^* mice have a depressive-like phenotype without perturbation of neurogenesis (Orvoen et al., [@B112]). Hence in HD, depression could be related to defects in other neuronal systems, such as raphe serotonergic neurons (see below).

The origin of defects of hippocampal neurogenesis may be non-cell autonomous, as is the case for *CaMKCreER^*T*2^*; *Htt^flox/flox^* mice. In these mice, HTT is specifically depleted in adult mature cortical and hippocampal neurons. However, new-born neurons show defects in dendritogenesis and survival, despite the fact that *Htt* is still expressed in these neurons (Pla et al., [@B122]). The phenotype of these new-born neurons is similar to that of TrkB-depleted new-born neurons (Bergami et al., [@B9]). This suggests that BDNF may be involved in the non-cell autonomous effect of mature neurons on new-born neurons.

Natural or induced changes to the abundance of BDNF have been associated with changes to adult hippocampal neurogenesis in several studies (Lee et al., [@B83]; Duman, [@B38]; Sairanen et al., [@B141]). However, although physical exercise promotes the production of BDNF, this is not associated with an improvement to hippocampal neurogenesis in various HD models (Kohl et al., [@B73]; Renoir et al., [@B131]). Thus, in the context of HD, the production of BDNF does not seem to restore normal hippocampal neurogenesis. The exercise-dependent stimulation of neurogenesis depends on PI3K-Akt signaling (Bruel-Jungerman et al., [@B14]), which acts downstream of BDNF/TrkB. Hence, the absence of a pro-neurogenic response to exercise in these HD models could be linked to the aforementioned defects of BDNF/TrkB signaling. Other players may also be involved, such as the serotonergic system.

HTT and the serotonergic signaling
==================================

Dysregulation of the raphe serotonergic system has been implicated as an important factor in mood disorders, including depression (Donaldson et al., [@B30]). Similarly, several observations point to a dysregulation of this system in HD. A study using transcranial ultrasound found a correlation between raphe echogenicity and the level of depression in patients with HD (Krogias et al., [@B76]). Concentrations of 5-hydroxytryptamine (5-HT) and its metabolite 5-hydroxyindolacetic acid (5-HIAA), which are often low in patients with major depression, are also low in HD patients (Caraceni et al., [@B16]; Jongen et al., [@B67]), whereas the activity of monoamine oxydase A enzyme activity (which catalyzes the breakdown of 5-HT) is high (Richards et al., [@B134]). Furthermore, 5-HT binding to its receptor is also impaired, as assessed in post-mortem HD brains (Waeber and Palacios, [@B164]; Steward et al., [@B151]; Wong et al., [@B168]). The Htr1A and Htr1B receptor subtypes appear to be particularly affected (Castro et al., [@B17]; Yohrling et al., [@B171]). The expression of serotonergic receptors is perturbed in murine HD models (Pang et al., [@B115]; Renoir et al., [@B131]). The expression of *Htr1a*, *Htr1b*, and *Htr2a* is low, whereas the expression of *Htr2c* is normal. Lower concentrations of serotonin (and also of 5-HIAA), dopamine, and noradrenaline were found in the striatum, cortex, and hippocampus of R6/1 mice compared to wild-type mice (Renoir et al., [@B132]).

The behavior of R6/1 mice, including its sex-specific component, resembles that of *Htr1a*^−/−^, or *Htr1b*^−/−^, or *SERT*^−/−^ mice (Gross et al., [@B56]; Mayorga et al., [@B96]; Holmes et al., [@B64]; Lira et al., [@B89]; Jones and Lucki, [@B66]). Gene expression studies have found changes to the expression of *Htr1a*, *Htrb1*, and *SERT* in the brains of R6/1 mice (Pang et al., [@B115]), suggesting that alterations of mood behavior in HD mice could be caused, at least in part, by a low abundance of these 5-HT receptors and this 5-HT transporter. The expression of *Htr1b* is lower in R6/1 females than in males (Pang et al., [@B115]), making *Htr1b* an obvious candidate to explain sex-specific differences in mood behavior. Female R6/1 mice are more sensitive than males to the Htr1a receptor agonist 8-OH DPAT in the 8-OH DPAT-induced hypothermia test, suggesting sex-specific Htr1a hypersensitivity (Renoir et al., [@B132], [@B131]). SSRI sertraline treatment in female R6/1 mice was associated with both a reduction in depressive-like behavior and in the hypersensitivity of Htr1a autoreceptors (Renoir et al., [@B131]). This is consistent with observations in humans because sertraline is more effective for the treatment of chronic depression in women than in men (Kornstein et al., [@B74]).

It is not known if mutant HTT directly affects the transcription of genes encoding serotonergic receptors or transporters. However, serotonergic signaling may affect the expression of *HTT*. Indeed, in *Htr1a/Htr1b* double KO mice, which have a hyperserotonergic phenotype and show anxiety-related behavior, the expression of *Htt* and other HD-related genes is perturbed (Xia et al., [@B169]).

Serotonergic signaling can affect hippocampal neurogenesis. This effect depends on the serotonin receptor involved, although the overall effect is pro-neurogenic (Klempin et al., [@B71]). Therefore, the low abundance of various serotonin receptors that is observed in the hippocampus in HD models (see above) could at least partially explain the defects in DG neurogenesis. TrkB is expressed on serotonergic raphe neurons and BDNF produced in the hippocampus can be retrogradely transported to the raphe (Anderson et al., [@B4]; Madhav et al., [@B92]). BDNF/TrkB signaling affects the function of serotonergic neurons. For example, *Bdnf*^+/−^ mice show changes in serotonergic innervations of the cortex, hypothalamus, and hippocampus (Lyons et al., [@B91]; Luellen et al., [@B90]) and it would be interesting to examine the densities of serotonergic innervations in HD models.

HTT and the HPA axis
====================

The hypothalamic-pituitary-adrenal axis (HPA) is the main regulator of the stress response. In the HPA axis, cortisol secretion is controlled by the hypothalamic corticotrophin releasing hormone (CRH) and pituitary adrenocorticotropic hormone (ACTH). Stress leads to the hyper-secretion of corticosteroids by the adrenal glands and this is associated with a high risk of anxiety and depression. Therefore, changes to the activity of the HPA axis are common in patients with depression (Antonijevic, [@B5]). Chronic treatment of rodents with corticosterone induces anxiety- and depression-related behavior (Ardayfio and Kim, [@B6]; Gourley et al., [@B53]; Murray et al., [@B106]; David et al., [@B27]). The acute or chronic administration of corticosterone in mice is associated with impairment of neurogenesis and poor neuronal survival in the hippocampus (Cameron and Gould, [@B15]; Karishma and Herbert, [@B69]; Murray et al., [@B106]; David et al., [@B27]).

HPA hyperactivity has been observed in HD patients (Heuser et al., [@B60]; Leblhuber et al., [@B82]; Björkqvist et al., [@B12]; Aziz et al., [@B182]). In saliva samples taken early in the morning, pre-symptomatic HD carriers show higher cortisol concentrations than controls (Van Duijn et al., [@B160]). During the early stages of HD, salivary concentrations of cortisol in the morning are higher in depressed patients than in non-depressed patients (Shirbin et al., [@B146]). High concentrations of cortisol have been measured in transgenic R6/2 mice (Björkqvist et al., [@B12]) but also specifically in female R6/1 mice subjected to physiological or pharmacological stresses (Du et al., [@B32]). This may explain the tendency of HD female mice to have more depressive-like phenotypes than HD male mice in various models. Furthermore, testosterone has a protective effect against HPA hyperactivity (Rubinow et al., [@B138]).

Conclusions and perspectives
============================

Studies of anxiety and depression have mainly focused on the hippocampus, serotonergic signaling, and to a lesser extent, the HPA axis (Figure [2](#F2){ref-type="fig"}). However, depression involves perturbations of many other regions such as the prefrontal cortex, the cingulate cortex, the striatum, the amygdala, and the thalamus (Nestler et al., [@B109]). In the context of HD, research has historically concentrated on perturbations to the striatum with a focus on motor control. However, striatal alterations have also been implicated in HD early cognitive defects like executive dysfunction (Peinemann et al., [@B118]) and future studies may also implicate striatal dysfunction in mood disorders in HD patients. All these regions are highly interconnected and mood disorders alter these circuits. It seems reasonable to think that depression and anxiety that are associated with HD have several origins within these circuits. Targeted deletion or KI mouse models could be used to answer this question. Recently, Du et al. ([@B33]) proposed that dysfunction of the HPA axis could trigger a cascade of events participating to mood disorders in patients with HD.

![**Many defects at various locations in the brain of HD murine models can be linked to mood disorders**. Studies in mouse models of HD have shown that BDNF/TrkB signaling is altered in various brain regions. Alterations of the serotonergic system and of the HPA axis have also been documented. AG, adrenal gland; Amy, amygdala; Ctx, cortex; Hip, hippocampus; Hyp, hypothalamus; Ra, raphe nuclei. See references in the text.](fnbeh-08-00135-g0002){#F2}

Defects in adult hippocampal neurogenesis have also been implicated in cognitive alteration of learning and memory, which are also present in HD. Therefore, the study of hippocampal neurogenesis will benefit not only our understanding of mood alterations in patients with HD, but also our understanding of cognitive deficits in these patients. In addition, BDNF has been implicated in hippocampal neurogenesis but is also involved in the development and maintenance of dendritic spines (Tyler and Pozzo-Miller, [@B158]; Alonso et al., [@B2]; Von Bohlen und Halbach et al., [@B162], [@B163]), as well as synaptic plasticity (Gomez-Palacio-Schjetnan and Escobar, [@B52]). Thus, defects of BDNF/TrkB signaling that are described for HD models may also affect cognition. In this regard, it is interesting to note that depression is also associated with poor cognitive performance in patients with HD (Smith et al., [@B150]).

HTT controls the intracellular trafficking of other ligands and receptors besides BDNF and TrkB. Perturbation of this trafficking in the presence of mutated HTT may also contribute to the pathology of mood disorders For example, polyQ-HTT alters GABA~A~R vesicle trafficking, resulting in the loss of GABA~A~R surface delivery and in a low inhibitory synaptic response (Twelvetrees et al., [@B157]; Yuen et al., [@B174]). GABA~A~R dysfunction is implicated in mood disorders (Rudolph and Möhler, [@B139]). GABA interneurons are inhibited by 5-HT1A receptors in basolateral amygdala, an area implicated in anxiety and fear processing (Rainnie, [@B127]). Moreover, NMDA receptor signaling pathways are perturbed in HD patients (Young et al., [@B172]). In transgenic YAC models of HD, alteration of NMDA receptor activity that affects long-term potentiation (LTP) is an early event prior to any motor or cognitive defects (Hodgson et al., [@B63]; Milnerwood and Raymond, [@B102]).

Another level of complexity that remains to be explored is the role of the various fragments of HTT that are generated during the progression of HD. Mutated HTT is cleaved by caspases. In particular, caspase-6 cleavage represents an important event mediating neuronal dysfunction and neurodegeneration (Gafni et al., [@B46]; Graham et al., [@B54]). YAC mice expressing a caspase-6-resistant mutant HTT exhibit only a moderate impairment of motor functions but also a modest depressive-like phenotype (Pouladi et al., [@B123]). These data suggest that caspase-6-mediated cleavage of HTT is an important trigger of depressive behavior. As some N-terminal fragments do not recapitulate full-length HTT functions, proteolysis event could be linked to the inactivation of HTT protein function.

BDNF release and signaling is decreased in the hippocampus in the context of HD, which is probably associated with the loss of HTT function in vesicular transport. However, BDNF signaling is increased in the amygdala and in the nucleus accumbens during major depression or stress disorders (Berton et al., [@B11]; Krishnan et al., [@B75]; Yu and Chen, [@B173]). Whether this is also true for depressed or stressed patients with HD and HD mouse models remains to be explored. If the activity of BDNF signaling is high in the amygdala and in the nucleus accumbens in the context of HD, then this would suggest that mutated HTT has region-specific effects on BDNF signaling. Little is known about the functions of HTT in the "fear" and in the reward systems where amygdala and nucleus accumbens are implicated respectively.

The underlying unresolved question is as follows: are the depressive symptoms observed for patients with HD different from those of individuals without HD? In other words, are the mechanisms at the basis of depression in patients with HD specific to this disease? The loss of HTT specifically in mature hippocampal neurons affects anxio-depressive behavior and the phosphorylation of HTT at S1181/1201 also appears to regulate mood-related behavior in mouse models of HD. These observations suggest that HTT is part of the physiological cascade controlling anxio-depressive behavior. Hence, the interest of studying HTT extends beyond HD. HTT could constitute a novel target for therapy in anxiety and depression both in patients with HD and in the general population. This could be important given that the effectiveness of currently available drugs is highly variable for many patients (Samuels and Hen, [@B142]; Kupfer et al., [@B77]).
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